AI assistant
Immunome Inc. — Director's Dealing 2020
Oct 2, 2020
32238_dirs_2020-10-01_beefc3f7-2969-412f-ad72-7fddcc2c49c6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-01
Reporting Person: Sarma Purnanand D (Director, President and CEO)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $0.54 | 2030-03-02 | Common Stock (328635) | Direct | |
| Employee Stock Option (right to buy) | $2.40 | 2030-08-03 | Common Stock (91840) | Direct | |
| Employee Stock Option (right to buy) | $2.40 | 2030-08-03 | Common Stock (51205) | Direct |
Footnotes
F1: One forty-eighth (1/48th) of the shares subject to the option vested or shall vest each month commencing June 30, 2019, subject to the
Reporting Person continuing to provide service through each such date.
F2: One forty-eighth (1/48th) of the shares subject to the option vested or shall vest each month commencing April 15, 2020, subject to the Reporting Person continuing to provide service through each such date.
F3: The shares subject to the option shall vest on November 1, 2024, subject to the Reporting Person continuing to provide service through each such date.